Hani Gabra is Emeritus Professor of Medical Oncology at Imperial College London and Honorary Consultant Medical Oncologist at Imperial College Healthcare NHS Trust, based at the Hammersmith Campus of Imperial College, since August 2020.
Previously, Hani was Professor of Medical Oncology at Imperial College London and Honorary Consultant Medical Oncologist at Imperial College Healthcare NHS Trust, based at the Hammersmith Campus of Imperial College.His appointments were held part-time concurrently a role as Chief Medical Officer at BerGenBio ASA in Oxford (2019-21), having previously held the concurrent position of Chief Physician Scientist and Vice President / Head of the Clinical Discovery Unit in Early Clinical Development within the IMED Biotech Unit at AstraZeneca in Cambridge (2017-19).
Until May 2017 he was Head of the Molecular Therapeutics Unit, Deputy Head of the Division of Cancer and Director of the Ovarian Cancer Action Research Centre at Imperial College, and at Imperial College Healthcare NHS Trust he was also Head of Medical Oncology and Chair of the Cancer Research Committee. Until May 2017 he was also Associate Director and Lead of the Cancer Division (Division 1) of the NIHR Clinical Research Network for North West London.
Hani studied Medicine at the University of Glasgow and graduated with a BSc (Hons) in Molecular Biology and MB ChB in 1987. After obtaining MRCP(UK) in 1990, he undertook an MSc in Clinical Oncology and a PhD in Molecular Oncology from the University of Edinburgh. He then completed his specialist training in Cancer Medicine in Edinburgh and was CRUK Clinical Scientist and Consultant Medical Oncologist at the CRUK Edinburgh Medical Oncology Unit from 1998-2003, following which he took up his Chair appointment at Imperial College.
He is a Fellow of the Royal College of Physicians of Edinburgh and London.
His research interests are in the roles of tumour suppressor genes in ovarian cancer, particularly how OPCML regulates networks of receptor tyrosine kinases and how WWOX acts to regulate taxane sensitivity.
His clinical / translational interests relate to the understanding of platinum resistance in ovarian cancer, and he has developed several molecular targets whose inhibition can reverse platinum resistance from laboratory to clinic; such targets include AKT, MTOR, HDAC4, STAT1 and the Folate Receptors.
Until September 2017 he was founding President of the European Translational Ovarian Cancer Network (EUTROC), a multinational group that undertakes science in ovarian cancer clinical trials, principally in the context of complex phase II clinical trials.
He previously sat on CRUK CTAAC funding committee for the UK and the INCa Scientific Evaluation Committee, Institut National Du Cancer of France.
et al., 2022, AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells., Cell Rep Med, Vol:3
et al., 2022, Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial, The Lancet, Vol:399, ISSN:0140-6736, Pages:541-553
et al., 2021, A novel application of calcium electroporation to cutaneous manifestations of gynaecological cancer, European Journal of Gynecological Oncology, Vol:42, ISSN:0392-2936, Pages:662-672
et al., 2021, The smell of oesophageal adenocarcinoma: opportunities for tests and treatments, OXFORD UNIV PRESS, ISSN:0007-1323
et al., 2021, A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy/safety of farletuzumab in combination with carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin (PLD) in women with low CA-125 platinum-sensitive ovarian cancer, ACADEMIC PRESS INC ELSEVIER SCIENCE, Pages:S38-S39, ISSN:0090-8258